细胞癌中的一线ICI
Vincenzo Fiorentino1, Pietro Tralongo2, Luigi Maria Larocca3
1Department of Human Pathology in Adult and Developmental Age "Gaetano Barresi", Pathology Section, University of Messina, Messina, Italy.
Human vaccines & immunotherapeutics
|July 3, 2023
概括
转移性细胞癌 (mRCC) 的治疗现在使用PD-1/PD-L1抑制等向疗法. 这些免疫检查点抑制剂恢复了身体对抗癌症的免疫反应,改善了患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 转移性细胞癌 (mRCC) 治疗已经显著发展.
- 传统的治疗方法,如干扰素α (IFN-α) 和高剂量介质素-2 (HD IL-2) 已经在很大程度上被取代.
- 新的向疗法侧重于瘤新血管生成,拉巴素 (mTOR) 途径的哺乳动物点,以及免疫检查点.
研究的目的:
- 审查目前对mRCC的治疗方案.
- 突出免疫检查点抑制剂 (ICI) 在mRCC治疗中的作用.
- 讨论ICI与其他药物的组合.
主要方法:
- 对mRCC的治疗方案的文献综述.
- 专注于涉及免疫检查点抑制剂 (ICI) 的研究.
- 分析治疗策略,包括单疗法和与ICI结合治疗.
主要成果:
- 免疫检查点抑制,特别是PD-1/PD-L1阻塞,现在是对mRCC的标准护理.
- ICI恢复抗瘤免疫反应,导致免疫介导的癌细胞消除.
- 抑制PD-1/PD-L1可以改善其他向疗法失败的mRCC患者的预后.
结论:
- 免疫检查点抑制剂代表了mRCC治疗的重大进步.
- ICI为mRCC患者提供了更好的结果,特别是在之前的向疗法后.
- 该审查涵盖基于ICI的协议,单独或与其他药物结合使用.
关键词:
免疫检查点抑制抑制相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Acute Kidney Injury IV: Diagnostic Studies and Prevention
37
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
37
Antihypertensive Drugs: Direct Renin Inhibitors
699
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
699
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Acute Kidney Injury I: Introduction
35
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
35


